top
Search terms
Results 1 - 10 of 10 - ordered by :
Ehjournal

In the second of a two-part review, we discuss the use of NOAC for stroke prevention in the following subgroups of patients with AF: (vii) secondary stroke prevention in patients after stroke or ...

European Heart Journal, Diener, Hans-Christoph, Aisenberg, James, Ansell, Jack, Atar, Dan, Breithardt, Günter, Eikelboom, John, Ezekowitz, Michael D., Granger, Christopher B., Halperin, Jonathan ...

Date : 09/03/2017
Ehjournal

[...]the authors found a correlation between plasma biomarkers of thrombin generation, fibrinolytic activity, and endothelial dysfunction with the presence of risk factors or conditions associated ...

European Heart Journal, Pastor-Pérez, Francisco J., Marín, Francisco, Manzano-Fernández, Sergio, Lip, Gregory Y.H.

Date : 01/12/2008 Item size : 121147 bytes
Ehjournal

[...]clinical trials of antithrombotic therapy in patients with AF have rightly included bleeding events as part of the composite primary endpoint, as treatment decisions should be based upon net ...

European Heart Journal, Lane, Deirdre A., Lip, Gregory Y.H.

Date : 01/09/2010
Ehjournal

Stroke prevention in atrial fibrillation: antiplatelet therapy revisitedThe opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the ...

European Heart Journal, Lip, Gregory Y.H., Watson, Timothy

Date : 01/04/2007 Item size : 122246 bytes
Ehjournal

Abstract Aims To establish the safety, tolerability and most promising regimen of darexaban (YM150), a novel, oral, direct factor Xa inhibitor, for prevention of ischaemic events in acute coronary ...

European Heart Journal, Steg, Ph. Gabriel, Mehta, Shamir R., Jukema, J. Wouter, Lip, Gregory Y.H., Gibson, C. Michael, Kovar, Frantisek, Kala, Petr, Garcia-Hernandez, Alberto, Renfurm, Ronny W., ...

Date : 01/10/2011
Ehjournal

In the second of a two-part review, we discuss the use of NOAC for stroke prevention in the following subgroups of patients with AF: (vii) secondary stroke prevention in patients after stroke or ...

European Heart Journal, Diener, Hans-Christoph, Aisenberg, James, Ansell, Jack, Atar, Dan, Breithardt, Günter, Eikelboom, John, Ezekowitz, Michael D., Granger, Christopher B., Halperin, Jonathan ...

Date : 21/03/2017
Ehjournal

Stroke prevention in atrial fibrillation: antiplatelet therapy revisitedThe opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the ...

European Heart Journal, Lip, Gregory Y.H., Watson, Timothy

Date : 01/04/2007
Ehjournal

Introduction Drug-eluting stents (DES) are a great advance in interventional cardiology because of their significant reduction of restenosis in relation to conventional bare-metal stents (BMS). DES ...

European Heart Journal, Ruiz-Nodar, Juan M., Marín, Francisco, Sánchez-Payá, José, Hurtado, José A., Valencia-Martín, José, Manzano-Fernández, Sergio, Roldán, Vanessa, ...

Date : 01/04/2009 Item size : 315821 bytes
Ehjournal

A meta-analysis1 of the 12 trials comparing dose-adjusted warfarin with antiplatelet therapy alone, including the largest trial to date, the Atrial Fibrillation Clopidogrel Trial with Irbesartan for ...

European Heart Journal, Lane, Deirdre A., Lip, Gregory Y.H.

Date : 01/09/2010 Item size : 116693 bytes
Ehjournal

In the second of a two-part review, we discuss the use of NOAC for stroke prevention in the following subgroups of patients with AF: (vii) secondary stroke prevention in patients after stroke or ...

European Heart Journal, Diener, Hans-Christoph, Aisenberg, James, Ansell, Jack, Atar, Dan, Breithardt, Günter, Eikelboom, John, Ezekowitz, Michael D., Granger, Christopher B., Halperin, Jonathan ...

Date : 21/03/2017 Item size : 512201 bytes